113239-57-9

Basic information

• Product Name: Acetyl chloride, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-
• CAS NO: 113239-57-9
• Molecular Formula: C13H11Cl3O3
• Molecular Weight: 321.588
• Mol File: 113239-57-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Acetyl chloride, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetyl chloride, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-(113239-57-9)
• EPA Substance Registry System: Acetyl chloride, [2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy]-(113239-57-9)

Safety Data

• Hazardous Substances Data: 113239-57-9(Hazardous Substances Data)

Upstream product

• 2350-46-1 2',3'-dichloro-4'-hydroxybutyrophenone 
• 1217-67-0 <2,3-dichloro-4-(1-oxobutyl)phenyloxy>acetic acid 
• 58-54-8 ethacrynic acid 

Downstream Products

• 327023-34-7 1-O-glycerol[2,3-dichloro-4-(2-methylenebutyryl)]phenoxyacetate 
• 29922-97-2 N-<<2,3-dichloro-4-(2-methylenebutyryl)phenoxy>acetyl>glycine 
• 1130160-82-5 C₁₉H₂₄Cl₂N₂O₄ 
• 1130160-97-2 C₁₉H₁₇Cl₂N₃O₆S 
• 1130161-00-0 C₂₀H₂₄Cl₂N₂O₄ 
• 1130160-88-1 C₁₉H₁₆Cl₂N₂O₅ 
• 224582-76-7 C₂₀H₁₆Cl₂N₂O₃S 
• 1130160-72-3 C₁₄H₁₄Cl₂N₂O₆ 
• 1130160-91-6 C₂₁H₁₉Cl₂N₃O₅ 
• 1130161-07-7 C₂₂H₂₀Cl₂N₂O₅ 
• 1130160-87-0 C₂₃H₂₂Cl₂N₂O₃ 
• 1130160-81-4 C₂₁H₁₆Cl₂N₂O₅ 
• 1130161-01-1 C₁₉H₁₆Cl₂N₂O₆ 
• 1130160-92-7 C₂₃H₁₉Cl₂NO₅ 

Relevant articles and documents

Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in?vitro and in?vivo

Platinum-based DNA-adducting agents are used extensively in the clinic for cancer chemotherapy. However, the anti-tumor efficacy of these drugs is severely limited by cisplatin resistance, and this can lead to the failure of chemotherapy. One of cisplatin

Novel antiglaucoma prodrugs and codrugs of ethacrynic acid

The purpose of this study was to synthesize a novel prodrug of ethacrynic acid (ECA) with short chain polyethylene glycols (PEGs) and codrugs of ECA with the β-adrenergic blocking agent atenolol (ATL) or timolol (TML) to overcome the adverse effects of EC

Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug

The cytotoxicity of cisplatin (cDDP) is enhanced when co-administered with ethacrynic acid (EA), a glutathione S-transferase (GST) inhibitor. A PtIV–EA conjugate containing a cDDP core and two axial ethacrynate ligands (compound 1) was shown to be an excellent inhibitor of GST, but did not readily release a PtII species to exert a synergistic cytotoxic effect. In this study, a redesigned PtIV construct composed of a cDDP core with one axial ethacrynate ligand and one axial hydroxido ligand (compound 2) was prepared and shown to overcome the limitations of compound 1. The EA ligand in 2 is readily released in vitro together with a cytotoxic PtII species derived from cisplatin, working together to inhibit cell proliferation in cDDP-resistant human ovarian cancer cells. The in vitro activity translates well in vivo with 2, showing effective (～80 %) inhibition of tumor growth in a human ovarian carcinoma A2780 tumor model, while showing considerably lower toxicity than cisplatin, thus validating the new design strategy.

Novel oxadiazole analogues derived from ethacrynic acid: Design, synthesis, and structure - Activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation

Ethacrynic acid (EA) is a glutathione S-transferase P1-1 (GST P1-1) inhibitor with weak antiproliferative ability in tumor cells. By use of the principle of bioisosterism, a series of novel EA oxadiazole analogues were designed and synthesized. The struct